Galicia (Spain) | Biotech Company
Nanoimmunotech is a nanobiotechnology Spanish SME with a wide knowledge in bioconjugation and biosensors. It was created in 2009 as a spin-off of two research centers with experience in different areas of nanobiotechnology. With venues in Zaragoza and Vigo, the company has great international presence, sells its products and services all over the world and cooperate in global R&D projects. With the purpose of becoming a world referent in nanobionsensors, they have launched to the market, HEATSENS®, a new disruptive technology of which the company has the exclusive patent and license.
Galicia (Spain) | Academic Institution; R&D Institution; Science & Technology Parks, Incubators, or Technology Transfer Organisations
With more than 1,000 researchers dedicated to biotechnology and biomedicine, a Campus of
International Excellence, CAMPUS VIDA, and 30 years of experience in valorization and
transfer of research results, the USC has a portfolio of more than 200 patents and 40 spin-off
based on the knowledge generated by its researchers.
Norte (Portugal) | Medtech Company
BestHealth4U is developing and bringing to market a new generation of medical-grade adhesives.
Bio2Skin is our revolutionary nano-based adhesive for medical applications and can be integrated into a wide range of medical devices. It is based on a patented-pending technology, that avoids skin injury in prolonged use or upon removal. It is ideal for general use and can provide effective protection against Medical Adhesive-Related Skin Injury (MARSI) in long-term applications such as ostomy, elderly and neo-natal patients. The treatment of the skin damage is costly in terms of service provision, time, and in severe cases requires long periods of hospitalizations due to infection. Besides mechanical injury, medical adhesives can induce dermatitis (either irritant or allergic) and other types of skin damage such as maceration of folliculitis. Age-related physiologic factors exert a significant impact on a patient’s susceptibility with the elderly and neonates the most vulnerable. In 2012, it was calculated that about €900 million in payments to hospitals in USA were withheld because of MARSI.
Currently available adhesives are artificially produced viscous materials that fill the skin irregularities, to augment the contact area. When they are removed, they tend to provoke dermatitis, which is due to the removal of a large amount of epidermis cells. Bio2Skin is inspired by forces in nature which results from the combination of highly biocompatible chemically-modified polymers. The adhesive developed by BestHealth4U uses polyol polymer produced based on bio-materials and modified polymers. Applications of these materials are based on their intrinsic biocompatibility, biodegradability, and non-toxicity.
Bio2Skin displays excellent adhesion properties to match currently used medical-grade adhesives. Bio2Skin binds to the natural features of the skin offering good adhesion properties without damaging the skin either during use or upon removal, reducing or even eliminating the skin damage caused by the continuous use of current adhesives. It can be used in ostomy, wound dressing, hot and cold therapy, wearable medical devices and kinesiology bands. Small-scale pre-clinical tests so far have been extremely promising, and we believe we can make a significant impact in the medical adhesive market which s is projected to reach €10 billion by 2019.
Mentoring | Advanced Therapy Medicinal Products; Pharmaceutical Products; Medical Technologies & In Vitro Diagnostics
The HealthTechTAB is a high-level EC-powered service that operates within the framework of NOBEL, a joint effort to accelerate HealthTech development and provide the HealthTech community, both from industry and academia, with the right tools to bring their innovations to patients.The TAB brings together a pool of industry experts with a solid track record of delivering health tech products from bench to the patients with the sole purpose of accelerating the translation of promising European health tech projects through high-level coaching. The TAB welcomes projects at any stage of development and offers them technical and commercial evaluation together with peer support and guidance. This service is accessible to all European innovators, from academia and industry, for free.For more information about the program, please visit https://healthtechtab.eu/ or contact us.
Norte (Portugal) | Science & Technology Parks, Incubators, or Technology Transfer Organisations
Founded in 1990, TecMinho is a private non-profit association, having had as sponsors the University of Minho and the Association of Municipalities of Vale do Ave. Its basic mission is to be an interface of the University of Minho, promoting its connection to society, especially in the areas of science and technology, contributing to regional development by improving the competitiveness of organizations and increase the skills of individuals.
Our quest for innovation and technological development takes place through 3 main lines of action:
TecMinho's Intervention Strategy:
- Promotion of innovation and development of new technologies / products / processes and their transfer to businesses;
- Promotion of Continuous Training activities (including e-learning), as well as organizational development and transnational mobility of human resources;
- Support to the creation of enterprises, with emphasis on academic spin-offs;
- Kick-start of projects of research / development, as well as guidance in its implementation.
Galicia (Spain) | Public / Nonprofit Organisation
ACIS is the autonomous public agency attached to the Ministry of Health that responds to the
need to manage training in the public health system of Galicia, to promote research in health
institutions, to promote and coordinate innovation in the health sector and to evaluate health
technologies, processes and services. ACIS is the nucleating element of the ecosystem of
knowledge and innovation in health in Galicia.
Norte (Portugal) | Pharmaceutical Company; R&D Institution
BIAL is an innovative pharmaceutical company with products available in more than 55 countries.
Founded in 1924, BIAL’s mission is to discover, develop and provide new therapeutic solutions within the area of Health. The company is committed to improve human health and quality of life for people from all over the world. Its strategic areas are Innovation, Internationalisation and Quality.
The company headquarters are located in Portugal. BIAL has also affiliates in Spain, Germany, United Kingdom, Italy, Switzerland, Mozambique, Angola, Ivory Coast and Panama.
Strongly committed to therapeutic innovation, and consistently investing more than 20% of its annual revenue in Research and Development (R&D), BIAL has established an ambitious R&D programme. Key focus areas for the Group are the neurosciences and cardiovascular.
BIAL has launched eslicarbazepine acetate, an epilepsy drug, already available in the US and in several European countries. BIAL has also developed a Parkinson’s disease compound, opicapone, also commercialized in Europe. The company expects to introduce more new medicines to the market over the next few years, strengthening its international presence based in its own innovative medicines and accomplishing the purpose of delivering innovative products to patients worldwide.
BIAL Group is a member of the “European Federation of Pharmaceutical Industries and Associations” (EFPIA).
Bioga y la Axencia Galega de Innovación organizan el próximo 15 de marzo en el Edificio Emprendia (Santiago de Compostela) el Bioalmorzo Blockchain “Casos de uso en biotecnología” en colaboración con la Asociación Galega Blockchain e IoT (AGALBIT). La jornada dará comienzo a las 10h.Para ello, contaremos con la participación de: Antonino Comesaña: Vicepresidente AGALBIT. Asociación Galega Blockchain e IoT (Ver CV).Pablo López: Asesor Business AGALBIT. Director Creativigo Consultores de Innovación (Ver CV).AGALBIT es una asociación sin ánimo de lucro que tiene como objetivo la divulgación de la tecnología Blockchain o Internet de la Cosas (IoT), así como cualquier sistema de computación descentralizado a particulares, empresas e instituciones.Blockchain junto con otras tecnologías como (IOT, Big Data, IA…) van a cambiar los modelos de negocios y ofrecer grandes oportunidades. En este encuentro hablaremos sobre qué es el blockchain, cómo está evolucionando y cómo puede ser de utilidad para sector biotecnológico.Expondremos casos de uso para reflexionar sobre ellos y exploraremos posibilidades reales para los asistentes (identidad digital, trazabilidad, registro y custodia de datos, smart contracts, tokenización). El objetivo del bioalmorzo es que los asistentes comprendan, de una forma práctica y sencilla qué es Blockchain, en que fase de desarrollo se encuentra actualmente y como puede ser aplicado en las empresas biotech.La asistencia es gratuita.Las personas que deseen asistir pueden inscribirse en la siguiente dirección de correo: email@example.com antes del 14 de marzo.
Norte (Portugal) | Academic Institution
The Portuguese Catholic University - UCP was created in 1967. Being a non-state entity, it enjoys a high degree of autonomy in the creation and operation of its units, facilities and courses. The UCP comprises 15 Faculties, Schools and Institutes that constitute the teaching and research units located in four regional centers (Braga, Porto, Beiras and Lisbon). In each of these Centers, transversal and complementary competences are identified in various fields of life and health sciences and technologies. The multi- and interdisciplinary nature of health research that is developed in the UCP is based mainly on postgraduate quality training, internationalization and establishing strong links with the industry sector. In this way, the UCP intends to intervene in a significant way in the scientific, economic and social communities through the development of R&D activities in areas ranging from biotechnology (food, environment and biomedical) to health care and aging, exploring current societal challenges for health promotion and well-being.